Suppr超能文献

鞣花酸和番泻苷B通过抑制c-Jun的表达来抑制骨肉瘤细胞的迁移、侵袭和生长。

Ellagic acid and Sennoside B inhibit osteosarcoma cell migration, invasion and growth by repressing the expression of c-Jun.

作者信息

Xu Wei, Xu Jinjin, Wang Ting, Liu Weibo, Wei Haifeng, Yang Xinghai, Yan Wangjun, Zhou Wang, Xiao Jianru

机构信息

Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.

Shanghai Key Laboratory of Regulatory Biology, Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), Institute of Biomedical Sciences, East China Normal University, Shanghai 200241, P.R. China.

出版信息

Oncol Lett. 2018 Jul;16(1):898-904. doi: 10.3892/ol.2018.8712. Epub 2018 May 16.

Abstract

Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma that is the most frequently diagnosed primary malignant bone tumor. Today, chemoprevention is regarded as a promising and realistic approach in the prevention of human cancer. Previous studies have suggested ellagic acid (EA) and Sennoside B have potential in this regard. The aim of the present study was to elucidate the anti-osteosarcoma effects of EA and Sennoside B by using Saos-2 and MG63 osteosarcoma cells. It was identified that EA or Sennoside B treatment could inhibit the growth, migration and invasion of the cells, and induce G cell cycle arrest by repressing the transcription of c-Jun. These results may provide a cellular basis for the application of EA or Sennoside B in the treatment of patients with osteosarcoma.

摘要

骨肉瘤是一种间充质来源的高级别骨肉瘤,是最常被诊断出的原发性恶性骨肿瘤。如今,化学预防被视为预防人类癌症的一种有前景且切实可行的方法。先前的研究表明,鞣花酸(EA)和番泻苷B在这方面具有潜力。本研究的目的是通过使用Saos-2和MG63骨肉瘤细胞来阐明EA和番泻苷B的抗骨肉瘤作用。研究发现,EA或番泻苷B处理可抑制细胞的生长、迁移和侵袭,并通过抑制c-Jun的转录诱导G期细胞周期停滞。这些结果可能为EA或番泻苷B在骨肉瘤患者治疗中的应用提供细胞基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7979/6019914/d848b15fa7d3/ol-16-01-0898-g00.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验